Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment

@article{Urgert2015OmalizumabIP,
  title={Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment},
  author={M. C. Urgert and M. T. van den Elzen and Andr{\'e} Knulst and Zbys Fedorowicz and Esther J van Zuuren},
  journal={British Journal of Dermatology},
  year={2015},
  volume={173}
}
Chronic spontaneous urticaria (CSU) is characterized by the occurrence of hives, angio‐oedema or both for a period of at least 6 weeks. Many patients remain symptomatic despite treatment with H1 antihistamines, even at higher doses. This systematic review assessed the quality of the evidence for the effects of omalizumab as treatment in patients with CSU. We searched PubMed, the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials up to 7 August 2014… 

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU) and results in clinically meaningful improvements of the UAS7, the ISS7, quality of life, and QoL (high certainty) (Dermatology Life Quality Index).

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.

Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria

Omalizumab is a good treatment option, thanks to its efficacy and safety, in chronic spontaneous urticaria patients who do not respond to H1-antihistamines.

The Use of Omalizumab in Chronic Urticaria: Available Data and Future Aspects of Anti-IgE Treatment

  • Y. Ye
  • Medicine, Biology
  • 2021
A new anti-IgE treatment, ligelIZumab is actively evaluated in the efficacy compared with both placebo and omalizumab, and further understandings on the pathogenesis of CU can lead to the development of new mechanism-based therapeutics for CU patients.

Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.

Effect of Diet in Chronic Spontaneous Urticaria: A Systematic Review.

The level of evidence is low for the benefit of systematic diets in CSU because systematic double-blind controlled trials of diet are lacking and the only randomized studies were based on oral provocation tests with the suspected responsible diet.

Omalizumab for chronic spontaneous urticaria: a boon for sufferers, but there are unanswered questions

  • M. Greaves
  • Medicine
    The British journal of dermatology
  • 2015
Omalizumab was impressive in its efficacy and tolerability, with adverse events being relatively minor, and the quality of evidence supporting these conclusions is high, but there remain nagging uncertainties.

Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress

The current challenges in the treatment of CSU, the pathogenesis and potential target molecules, and the rationale for novel treatments and their rapidly developing status are reviewed.
...

References

SHOWING 1-10 OF 31 REFERENCES

Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

It was observed that the use of omalizumab 300 mg lowered the weekly scores of urticarial activity in 19.9 vs. 6.9 on placebo, and it is considered that omalIZumab300 mg is effective in treating chronic idiopathic urticaria refractory to conventional treatment.

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU patients who remained symptomatic despite treatment with approved doses of H1 antihistamines.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic / Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines : A Randomized , Placebo-Controlled Study

The safety and effectiveness of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study are studied.

Response to: ‘Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal’

The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients, and the effectiveness and safety of canakinumab in urticarial vasculitis: an open-label study.

Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal

The efficacy and safety of omalizumab (an IgE monoclonal antibody) in patients with moderate‐to‐severe chronic idiopathic urticaria who remain symptomatic despite H1‐antihistamine therapy at licensed doses is evaluated.